赛隆药业(002898) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥38,408,703.27, a decrease of 9.98% year-on-year, and a significant decline of 41.00% for the year-to-date period[7] - The net profit attributable to shareholders was a loss of ¥8,355,818.45, representing a 529.45% increase in loss compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥9,002,027.35, an increase in loss of 648.19% year-on-year[7] - The company reported a net loss of ¥21,568,786.50, a decline of 214.14% compared to a profit of ¥18,896,088.38 in the previous year[16] - The total comprehensive loss for the period was ¥21,568,786.50, compared to a comprehensive income of ¥18,896,088.38 in the previous year[52] - The total operating revenue for the current year is ¥126,844,155.03, a decrease of 41.00% compared to ¥214,993,185.01 in the same period last year[15] - The company's operating revenue for the third quarter was ¥75,066,093.64, a decrease of 60.4% compared to ¥189,486,594.60 in the same period last year[55] - The net loss for the quarter was ¥50,553,855.42, compared to a net loss of ¥42,565,960.78 in the previous year, indicating a 18.7% increase in losses[56] Cash Flow - The net cash flow from operating activities was a negative ¥7,970,895.41, worsening by 64.86% compared to the previous year[7] - Cash received from operating activities increased by 162.85% to ¥14,410,461.11, compared to ¥5,482,321.23 in the previous year[17] - Cash flow from operating activities showed a net outflow of ¥13,222,283.85, an improvement from a net outflow of ¥60,571,392.22 in the previous year[57] - The net cash flow from investing activities was -33,295,291.46, an improvement from -82,345,097.28 in the prior period[62] - The net cash flow from financing activities was 11,270,217.17, compared to 19,579,945.30 in the previous period[63] Assets and Liabilities - Total assets at the end of the reporting period reached ¥892,068,106.50, an increase of 6.71% compared to the previous year[7] - The company's current assets reached CNY 336,391,389.37, compared to CNY 323,028,334.04 at the end of 2019, reflecting a growth of approximately 4.23%[33] - Total liabilities increased to CNY 259,412,568.36 from CNY 176,954,005.49, marking a rise of about 46.41%[35] - The equity capital increased to CNY 176,000,000.00 from CNY 160,000,000.00, reflecting a growth of 10%[35] - The company's retained earnings turned negative, showing a deficit of CNY 6,856,794.57 compared to a profit of CNY 48,497,060.85 at the end of 2019[39] Shareholder Information - The company reported a total of 13,982 shareholders at the end of the reporting period[10] - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, with 90,016,937 shares, of which 67,512,702 are pledged[10] Research and Development - Research and development expenses increased by 96.20% to ¥16,231,580.53, up from ¥8,272,814.48, due to increased investment in R&D projects[15] - The company reported a significant increase in R&D expenses to CNY 6,505,210.03 from CNY 3,415,974.30 year-on-year[42] - Research and development expenses rose significantly to ¥4,641,389.37, an increase of 34.5% from ¥3,449,003.82[46] Financial Position - The company has not engaged in any repurchase transactions during the reporting period[11] - The company has utilized CNY 40,000,000 of idle raised funds to temporarily supplement working capital, ensuring no impact on the construction of investment projects[26] - The company has no significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[28] - The report was not audited, indicating that the figures may be subject to change upon final review[73] - The company implemented new revenue and leasing standards starting in 2020, affecting the recognition of contract liabilities[72]